Local view for "http://purl.org/linkedpolitics/eu/plenary/2012-05-10-Speech-4-316-500"

Predicate	Value (sorted: default)
rdf:type	lpv_eu:Speech2
dcterms:Date	"2012-05-10"^^xsd:date2
dcterms:Is Part Of	lp_eu:Explanations of vote2
dcterms:Language	"ro"^^xsd:language2
lpv:document identification number	"en.20120510.69.4-316-500"2
lpv:hasSubsequent	lp_eu:2012-05-10-Speech-4-316-6252
lpv:speaker	lp:Monica Macovei2
lpv:spokenAs	member; LIBE (2012-01-19--2014-06-30)3,3 member; Conference of Delegation Chairs (2009-09-17--2014-06-30)3,3 member; EPP (2009-07-14--2014-06-30)3,3 chair; Delegation to the EU-Moldova Parliamentary Cooperation Committee (2009-09-17--2014-06-30)3,3 unknown; Partidul Democrat-Liberal (2009-07-14--2014-06-30)3,3 substitute; Delegation to the EU-Former Yugoslav Republic of Macedonia Joint Parliamentary Committee (2009-09-16--2014-06-30)3,3 substitute; AFET (2012-01-19--2014-06-30)3,3 member; CRIM (2012-03-28--2013-10-23)3,3 member; CONT (2012-01-19--2014-06-30)3,3 member; Delegation to the Euronest Parliamentary Assembly (2009-09-16--2014-06-30)3,3
lpv:translated text	"The report on the 2010 discharge for the European Medicines Agency provided for postponement of the discharge. I certainly voted in favour of this report as rapporteur and the one who proposed the postponement of the discharge. During the 2009 discharge procedure, the European Parliament requested a multiannual procurement plan from EMA, which has not yet been adopted. Moreover, the management board refused a new payment system for the agency, hence the management board accepts and takes direct responsibility for very important risks, such as non-compliance with legislative requirements, the potential financial impact of the current remuneration system, as well as reputation. Serious weaknesses in terms of conflicts of interest also remain. Its approach on the scrutiny of declarations of interest is based on trust rather than on verification of the experts’ declaration of interest published by the relevant national agencies. A genuine mechanism enabling proper scrutiny of the declarations of interest recently adopted by the agency must be implemented and show concrete results. The CV of its experts should be made available on its website. Consumers and, at the same time, taxpayers should be aware of who, how and why drugs are recommended and used by citizens."@en1
lpv:unclassifiedMetadata	"Monica Luisa Macovei (PPE ),"1 "in writing."1

Named graphs describing this resource:

The resource appears as object in 2 triples

Context graph